News - Lilly


Current filters:


Popular Filters

Lilly’s Cyramza disappoints in Ph III liver cancer trial

Lilly’s Cyramza disappoints in Ph III liver cancer trial


US drug major Eli Lilly (NYSE: LLY) says the Phase III REACH trial of Cyramza (ramucirumab) in patients…

ChemistryCyramzaEli LillyHealth Medical PharmaLillyMajorOncologyOrganic chemistryPharmaceuticalResearch

UK’s NICE issues draft guidance on suite of ovarian cancer drugs


Drugs watchdog the National Institute for Health and Care Excellence (NICE) is currently considering…

Europegemcitabine HclGlaxoSmithKlineJohnson & JohnsonLillyOncologyPharmaceuticalPricingRegulationtrabectedin

More highlights from ASCO for: Eisai's Halaven; Boehringer's nintedanib; and Lilly's Alimta


Among further highlights from the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AlimtaBoehringer IngelheimEisaiHalavenLillynintedanibOncologyPharmaceuticalResearch

Eli Lilly views additional $180 million investment to expand insulin making in Indianapolis


US pharma major Eli Lilly (NYSE: LLY) says that it is working closely with the City on a proposal to…

DiabetesFinancialInsulinLillyNorth AmericaPharmaceuticalProduction

Back to top